Are Selective Serotonin Reuptake Inhibitors a Secondary Cause of Low Bone Density?

Background. Osteoporosis is a chronic disease that can significantly impact numerous aspects of health and wellness. The individual consequences of osteoporosis can be devastating, often resulting in substantial loss of independence and sometimes death. One of the few illnesses with greater disease...

Full description

Saved in:
Bibliographic Details
Main Authors: Kim Chau, Stephanie A. Atkinson, Valerie H. Taylor
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Journal of Osteoporosis
Online Access:http://dx.doi.org/10.1155/2012/323061
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832561058285355008
author Kim Chau
Stephanie A. Atkinson
Valerie H. Taylor
author_facet Kim Chau
Stephanie A. Atkinson
Valerie H. Taylor
author_sort Kim Chau
collection DOAJ
description Background. Osteoporosis is a chronic disease that can significantly impact numerous aspects of health and wellness. The individual consequences of osteoporosis can be devastating, often resulting in substantial loss of independence and sometimes death. One of the few illnesses with greater disease burden than low bone mineral density (BMD) is major depressive disorder (MDD). Both depression and antidepressant use have been identified as secondary causes of osteoporosis. The objective of this paper is to review and summarize the current findings on the relationship between antidepressant use and BMD. Methods. Relevant sources were identified from the Pubmed and MEDLINE databases, citing articles from the first relevant publication to September 1st, 2010. Results. 2001 articles initially met the search criteria, and 35 studies were thoroughly reviewed for evidence of an association between SSRI use and BMD, and 8 clinical studies were detailed and summarized in this paper. Conclusions. Current findings suggest a link between mental illness and osteoporosis that is of clinical relevance. Additional longitudinal studies and further research on possible mechanisms surrounding the association between SSRI use on bone metabolism need to be conducted. Treatment algorithms need to recognize this association to ensure that vulnerable populations are screened.
format Article
id doaj-art-2eae6fc2b5274a1c8ab3474d507ac98c
institution Kabale University
issn 2090-8059
2042-0064
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Journal of Osteoporosis
spelling doaj-art-2eae6fc2b5274a1c8ab3474d507ac98c2025-02-03T01:26:02ZengWileyJournal of Osteoporosis2090-80592042-00642012-01-01201210.1155/2012/323061323061Are Selective Serotonin Reuptake Inhibitors a Secondary Cause of Low Bone Density?Kim Chau0Stephanie A. Atkinson1Valerie H. Taylor2Department of Paediatrics, McMaster University, Hamilton, ON, L8S 4L8, CanadaDepartment of Paediatrics, McMaster University, Hamilton, ON, L8S 4L8, CanadaDepartment of Psychiatry, University of Toronto, Toronto, ON, L8S 4L8, CanadaBackground. Osteoporosis is a chronic disease that can significantly impact numerous aspects of health and wellness. The individual consequences of osteoporosis can be devastating, often resulting in substantial loss of independence and sometimes death. One of the few illnesses with greater disease burden than low bone mineral density (BMD) is major depressive disorder (MDD). Both depression and antidepressant use have been identified as secondary causes of osteoporosis. The objective of this paper is to review and summarize the current findings on the relationship between antidepressant use and BMD. Methods. Relevant sources were identified from the Pubmed and MEDLINE databases, citing articles from the first relevant publication to September 1st, 2010. Results. 2001 articles initially met the search criteria, and 35 studies were thoroughly reviewed for evidence of an association between SSRI use and BMD, and 8 clinical studies were detailed and summarized in this paper. Conclusions. Current findings suggest a link between mental illness and osteoporosis that is of clinical relevance. Additional longitudinal studies and further research on possible mechanisms surrounding the association between SSRI use on bone metabolism need to be conducted. Treatment algorithms need to recognize this association to ensure that vulnerable populations are screened.http://dx.doi.org/10.1155/2012/323061
spellingShingle Kim Chau
Stephanie A. Atkinson
Valerie H. Taylor
Are Selective Serotonin Reuptake Inhibitors a Secondary Cause of Low Bone Density?
Journal of Osteoporosis
title Are Selective Serotonin Reuptake Inhibitors a Secondary Cause of Low Bone Density?
title_full Are Selective Serotonin Reuptake Inhibitors a Secondary Cause of Low Bone Density?
title_fullStr Are Selective Serotonin Reuptake Inhibitors a Secondary Cause of Low Bone Density?
title_full_unstemmed Are Selective Serotonin Reuptake Inhibitors a Secondary Cause of Low Bone Density?
title_short Are Selective Serotonin Reuptake Inhibitors a Secondary Cause of Low Bone Density?
title_sort are selective serotonin reuptake inhibitors a secondary cause of low bone density
url http://dx.doi.org/10.1155/2012/323061
work_keys_str_mv AT kimchau areselectiveserotoninreuptakeinhibitorsasecondarycauseoflowbonedensity
AT stephanieaatkinson areselectiveserotoninreuptakeinhibitorsasecondarycauseoflowbonedensity
AT valeriehtaylor areselectiveserotoninreuptakeinhibitorsasecondarycauseoflowbonedensity